Dr. D’Amato and Dr. Frank Sparadeo, Calmar’s Director of Clinical Research, have collaborated with physicians from Johns Hopkins, Mayo Clinic, MD Anderson, and other leading institutions on published Scrambler Therapy research studies. Their work includes a 2016 review study published in Support Care Cancer analyzing 20 clinical ST studies and highlighting Calmar’s clinical success. They also contributed to the 2017 medical textbook Comprehensive Pain Management in the Rehabilitation Patient published through Brown University’s Warren Alpert Medical School.
Calmar has also become a recognized provider for Workers’ Compensation patients suffering from severe chronic neuropathic pain. Multiple Workers’ Compensation courts have ordered insurance reimbursement for ST treatment, and more than 73 insurance companies — including numerous WC carriers — have reimbursed Calmar patients for care. With unmatched clinical experience and a focus on long-term relief without invasive procedures or narcotics, Calmar continues to lead the field of Scrambler Therapy treatment in the United States.
Calmar utilizes Scrambler Therapy, an FDA-cleared treatment designed to reduce severe chronic neuropathic pain without surgery or narcotics. Using advanced neurostimulation technology, ST works by replacing pain signals with synthetic “non-pain” information to help retrain the nervous system.
If you believe you are a candidate for Scrambler Therapy, or you just want to learn more about this amazing technology or our practice, please reach out right away!
